Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clopidogrel combined with rivaroxaban vs aspirin in coronary heart disease with gastrointestinal disease undergoing PCI
ChiCTR2100044319Phase 4Recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in coronary arteriosclerosis, acute coronary syndrome (ACS), gastrointestinal conditions and 4 more comparing clopidogrel + rivaroxaban with clopidogrel + aspirin (2 arms). Primary endpoint: moderate and severe bleeding events (BARC 2-5). Started Apr 2021; status: recruiting.
02
Drugs
clopidogrelrivaroxabanaspirin
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)gastrointestinal conditionsPeptic ulcer disease (PUD)gastritis
Beyond the preview
Go deeper on ChiCTR2100044319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044319.